Combined blockade of ATR and PARP is an effective therapeutic strategy for GBM, even in non-Myc PARPi-resistant GSCs, thus providing a much-needed therapeutic breakthrough for this deadly disease and possibly other BRCA1/2-wild-type or HR proficient cancers. The gene discussed is PARP1; the disease is glioblastoma.